What is Zacks Research's Forecast for Surmodics Q2 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Zacks Research lowered their Q2 2026 EPS estimates for shares of Surmodics in a research note issued on Tuesday, May 27th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.01 per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.08 EPS, Q1 2027 earnings at $0.01 EPS and FY2027 earnings at $0.29 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The company had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Other research analysts also recently issued research reports about the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Wall Street Zen began coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a "hold" rating for the company. Finally, Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th.

Surmodics Price Performance

Surmodics stock traded down $0.49 during mid-day trading on Thursday, hitting $29.04. The stock had a trading volume of 41,419 shares, compared to its average volume of 262,780. The firm has a market capitalization of $415.24 million, a P/E ratio of -28.75 and a beta of 1.32. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The firm's 50 day moving average is $28.71 and its 200 day moving average is $33.57. Surmodics has a one year low of $26.00 and a one year high of $42.44.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Gabelli Funds LLC lifted its holdings in shares of Surmodics by 16.3% in the 1st quarter. Gabelli Funds LLC now owns 395,509 shares of the company's stock valued at $12,075,000 after acquiring an additional 55,550 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in shares of Surmodics in the 4th quarter valued at about $11,880,000. Hsbc Holdings PLC lifted its holdings in shares of Surmodics by 4.8% in the 1st quarter. Hsbc Holdings PLC now owns 267,042 shares of the company's stock valued at $8,252,000 after acquiring an additional 12,344 shares during the last quarter. Gardner Lewis Asset Management L P lifted its holdings in shares of Surmodics by 23.5% in the 4th quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock valued at $10,410,000 after acquiring an additional 49,944 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Surmodics by 71.6% in the 1st quarter. Millennium Management LLC now owns 206,487 shares of the company's stock valued at $6,304,000 after acquiring an additional 86,143 shares during the last quarter. Institutional investors own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).